Why lipoprotein(a) matters for clinical decisions and patient risk?

Martha Gulati shares her insights on lipoprotein(a) and atherosclerotic cardiovascular disease at the American College of Cardiology’s Annual Scientific Session. She discussed studies such as HORIZON and the ALPACA trial.

Chief Medical Officer's take on ACC.25

Richard Kovacs shares his insights on key announcements and findings at the American College of Cardiology’s Annual Scientific Session.

Arrhythmia Management: Updates From Recent Practice Guidance Documents

John K. Triedman shares his insights on the joint symposium of the Heart Rhythm Society and the American College of Cardiology, that will highlight recent guidelines and consensus documents in the arrhythmia field and updates since their publication. It's covering atrial fibrillation, conduction system pacing, management of arrhythmias in pregnancy, and management of athletes with arrhythmias.

Chronic Coronary Disease Management in 2025: What's New in the Guidelines?

Benjamin H. Freed co-chaired an interesting session on Chronic Coronary Disease Management in 2025 at the American College of Cardiology’s Annual Scientific Session.

Highlights of ACC.25

Hadley Wilson, ACC Immediate Past President shares his insights on the key announcements and findings at the American College of Cardiology’s Annual Scientific Session.

From Evidence Generation to Implementation: Tackling Unmet Need in ASCVD

Ankeet S. Bhatt shares his insights how real-world evidence and implementation science can improve ASCVD care at the American College of Cardiology’s Annual Scientific Session.

ALIGN-AR reports positive outcomes with dedicated TAVI device for aortic regurgitation

Raj Makkar explains data from 500 patients treated for aortic regurgitation with the Trilogy transcatheter aortic valve implantation system, point towards positive safety and efficacy outcomes with the device, alongside favourable valve performance at up to two years, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Shifting the Paradigm: Lipoprotein(a) in Cardiovascular Disease

Alan Brown shares his insights on lipoprotein(a) and atherosclerotic cardiovascular disease at the American College of Cardiology’s Annual Scientific Session. Why lipoprotein(a) matters for clinical decisions and patient risk?

Lorundrostat shows continued promise against uncontrolled hypertension

Luke Laffin on the phase 2b Advance-HTN study of lorundrostat, whose results were reported in a late-breaking clinical trials presentation at the American College of Cardiology’s 2025 Scientific Session.

Nurse-led behavior changes after heart attack cut subsequent event risk by 30%

Giulia Magnani explains a nurse-coordinated intensive intervention program emphasizing lifestyle and behavioral changes after ACS was associated with a 30% reduction in major adverse CV events for patients, primarily driven by a reduction in nonfatal MI, according to a study presented at the American College of Cardiology’s Annual Scientific Session.

Dapagliflozin Reduced LVMI in Patients with CKD : DECODE-CKD

Tor Biering-Sørensen presented the analysis of the primary and secondary endpoint results of the DECODE-CKD at the American College of Cardiology’s Annual Scientific Session.

Lifetime Benefit by Control of Modifiable Risk Factors

Christina Magnussen on individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause at the American College of Cardiology’s Annual Scientific Session.

Discussion on Optimizing Hypertension Management: We Need New Treatment and Interventions

Paul K. Whelton shares his insights on optimizing hypertension management at the American College of Cardiology’s Annual Scientific Session.

WARRIOR study: Intensive medical therapy does not help or harm women with chest pain

Eileen M. Handberg, PhD, ARNP, FACC and C. Noel Bairey Merz, MD, FACC, FAHA shares their  insights on the WARRIOR study, presented at the American College of Cardiology Scientific Session.

Low-dose apixiban comparable to full dose for preventing VTE recurrence in patients with cancer

Isabelle Mahé shares her insights API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session.

Research shows clopidogrel as better long-term therapy than aspirin after PCI - report from ACC.25

Joo-Yong Hahn shares his insights on the research presented at the American College of Cardiology's Annual Scientific Session. People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel rather than aspirin as their long-term antiplatelet therapy, according to Research.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention